Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: AzurRx BioPharma Inc. AZRX

AzurRx BioPharma Inc. (NASDAQ: AZRX) is “One to Watch”

AzurRx BioPharma’s lead therapeutic, MS1819, is a recombinant lipase treatment for exocrine pancreatic insufficiency and is currently targeting patients with cystic fibrosis and chronic pancreatitis – an established global market of more than $2 billion The company is currently pursuing … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials

AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment